MX2023010925A - Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables. - Google Patents

Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables.

Info

Publication number
MX2023010925A
MX2023010925A MX2023010925A MX2023010925A MX2023010925A MX 2023010925 A MX2023010925 A MX 2023010925A MX 2023010925 A MX2023010925 A MX 2023010925A MX 2023010925 A MX2023010925 A MX 2023010925A MX 2023010925 A MX2023010925 A MX 2023010925A
Authority
MX
Mexico
Prior art keywords
risperidone
injectable formulation
biodegradable polymers
long acting
acting injectable
Prior art date
Application number
MX2023010925A
Other languages
English (en)
Spanish (es)
Inventor
Eran Harary
Wagner Avia Merenlender
Valitsky Anna Elgart
Original Assignee
Medincell S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medincell S A filed Critical Medincell S A
Publication of MX2023010925A publication Critical patent/MX2023010925A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2023010925A 2021-03-17 2022-03-17 Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables. MX2023010925A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163162272P 2021-03-17 2021-03-17
IB2021052248 2021-03-17
US202163208860P 2021-06-09 2021-06-09
US202163270174P 2021-10-21 2021-10-21
PCT/EP2022/057009 WO2022195018A1 (en) 2021-03-17 2022-03-17 Long acting injectable formulation comprising risperidone and biodegradable polymers

Publications (1)

Publication Number Publication Date
MX2023010925A true MX2023010925A (es) 2023-09-27

Family

ID=81307068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010925A MX2023010925A (es) 2021-03-17 2022-03-17 Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables.

Country Status (10)

Country Link
US (2) US20240148641A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308077A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024511353A (cg-RX-API-DMAC7.html)
KR (1) KR20230158088A (cg-RX-API-DMAC7.html)
AU (1) AU2022236485A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018652A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208006A1 (cg-RX-API-DMAC7.html)
IL (1) IL304980A (cg-RX-API-DMAC7.html)
MX (1) MX2023010925A (cg-RX-API-DMAC7.html)
WO (1) WO2022195018A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010313290A1 (en) * 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
US10463607B2 (en) * 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
KR101424163B1 (ko) * 2010-12-24 2014-08-01 주식회사 삼양바이오팜 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법
MY165655A (en) 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
KR102189442B1 (ko) 2012-06-27 2020-12-11 메딘셀 에스.에이. 소수성 조성물용 생분해성 약물 전달
US20190015415A1 (en) * 2015-09-30 2019-01-17 Indivior Uk Limited Methods for treating schizophrenia
CN107213136B (zh) * 2017-06-07 2021-06-01 广州帝奇医药技术有限公司 一种长效缓释药物制剂及其制备方法
US20210386745A1 (en) * 2019-01-22 2021-12-16 Indivior Uk Limited Methods for treating schizophrenia
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil

Also Published As

Publication number Publication date
AU2022236485A1 (en) 2023-08-24
US12329851B2 (en) 2025-06-17
US20240148641A1 (en) 2024-05-09
IL304980A (en) 2023-10-01
KR20230158088A (ko) 2023-11-17
WO2022195018A1 (en) 2022-09-22
JP2024511353A (ja) 2024-03-13
US20240325293A1 (en) 2024-10-03
EP4308077A1 (en) 2024-01-24
BR112023018652A2 (pt) 2023-10-03
CA3208006A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
LTPA2008007I1 (lt) N-pakeisti hidroksipirimidinono karboksamido ŽIV integrazės inhibitoriai
WO2002004001A3 (en) A composition for the delivery of live cells and methods of use
SI1441734T1 (sl) Dihidropirimidin karboksamidni inhibitorji HIV-integraze
MX2022003051A (es) Formulaciones para la administracion de farmacos.
WO2022173888A8 (en) Pharmaceutically acceptable salts of psilocin and uses thereof
MX2023012723A (es) Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.
DK1528931T3 (da) Dipeptidylpeptidase-IV-inhibitorer til reduktion af hastigheden af kronisk vægtforögelse
MX2021011727A (es) Composiciones y metodos para tratar enfermedades oculares.
WO2019139956A3 (en) Prevention and treatment of organ fibrosis
MX2025008012A (es) Composiciones de olanzapina y metodos de uso
WO2023196832A3 (en) Pharmaceutical composition and method for treatment of human immunodeficiency virus infections
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
BR112023018652A2 (pt) Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis
PH12022552645A1 (en) Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
MY198967A (en) Pharmaceutical compositions comprising meloxicam
ATE359800T1 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
ZA202202673B (en) Methods and compositions for treating endometriosis
MX2026001798A (es) Metodo para tratar o prevenir enfermedades relacionadas con el colesterol utilizando un inhibidor de pcsk9
MX2024000806A (es) Composiciones y métodos para prevenir y/o tratar enfermedades asociadas con la expresión de la interleuquina 23 (il-23).
MX2025013695A (es) Método para administrar un modulador dirigido al receptor 1 de esfingosina-1-fosfato y receptor 4 de esfingosina-1-fosfato (s1pr1 y s1pr4)
IL311561A (en) Polyacrylamide hydrogel for use in the treatment and/or prevention of osteoarthritis
MD3250G2 (ro) Metodă de tratament al sindromului cheroto-conjunctivitei sica
ATE326974T1 (de) Blockierung der anlagerung von keimen bei vögeln